IRAK1 deletion disrupts cardiac Toll/IL-1 signaling and protects against contractile dysfunction

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 285, Issue 2 54-2, 2003, Pages

  Thomas, James A ^a,b   Haudek, Sandra B ^a   Koroglu, Tolga ^a   Tsen, May F ^a   Bryant, Debora D ^a   White, D Jean ^b   Kusewitt, Donna F ^c   Horton, Jureta W ^b   Giroir, Brett P ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Contractile function; Genetically altered mice; Heart failure; Signal transduction

Indexed keywords

GENE PRODUCT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL PATHWAY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CYTOKINE PRODUCTION; EMBRYO; GENE DELETION; GENE INACTIVATION; HEART FAILURE; HEART MUSCLE CONTRACTILE FORCE; HEART PROTECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; MOUSE; MYOCARDITIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 0037623904     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.0655.2001     Document Type: Article

References (48)

1. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, and Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150, 1998.
2. Aikawa N, Martyn JA, and Burke JF. Pulmonary artery catheterization and thermodilution cardiac output determination in the management of critically burned patients. Am J Surg 135: 811-817, 1978.
3. Baumgarten G, Knuefermann P, Nozaki N, Sivasubramanian N, Mann DL, and Vallejo JG. In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of toll-like receptor-4. J Infect Dis 183: 1617-1624, 2001.
4. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, Thompson M, and Giroir B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 97: 1375-1381, 1998.
5. Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, and Harken AH. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 27: 1309-1318, 1999.
6. Cao Z, Henzel WJ, and Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science 271: 1128-1131, 1996.
7. Cao Z, Xiong J, Takeuchi M, Kurama T, and Goeddel DV. TRAF6 is a signal transducer for interleukin-1. Nature 383: 443-446, 1996.
8. Dawn B, Xuan YT, Marian M, Flaherty MP, Murphree SS, Smith TL, Bolli R, and Jones WK. Cardiac-specific abrogation of NF-kappa B activation in mice by transdominant expression of a mutant I kappa B alpha. J Mol Cell Cardiol 33: 161-173, 2001.
9. Flesch M, Kilter H, Cremers B, Laufs U, Sudkamp M, Ortmann M, Muller FU, and Bohm M. Effects of endotoxin on human myocardial contractility involvement of nitric oxide and peroxynitrite. J Am Coll Cardiol 33: 1062-1070, 1999.
10. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, and Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104: 271-280, 1999.
11. Giroir BP, Johnson JH, Brown T, Allen GL, and Beutler B. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 90: 693-698, 1992.
12. Hambleton J, Weinstein SL, Lem L, and DeFranco AL. Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proc Natl Acad Sci USA 93: 2774-2778, 1996.
13. Hardiman G, Rock FL, Balasubramanian S, Kastelein RA, and Bazan JF. Molecular characterization and modular analysis of human MyD88. Oncogene 13: 2467-2475, 1996.
14. Haudek SB, Spencer E, Bryant DD, White DJ, Maass D, Horton JW, Chen ZJ, and Giroir BP. Overexpression of cardiac IκBα prevents endotoxin-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol 280: H962-H968, 2001.
15. Kanakaraj P, Schafer PH, Cavender DE, Wu Y, Ngo K, Grealish PF, Wadsworth SA, Peterson PA, Siekierka JJ, Harris CA, and Fung-Leung WP. Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. J Exp Med 187: 2073-2079, 1998.
16. Kawai T, Adachi O, Ogawa T, Takeda K, and Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115-122, 1999.
17. Kloner RA and Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. Circulation 104: 2981-2989, 2001.
18. Levine B, Kalman J, Mayer L, Fillit HM, and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323: 236-241, 1990.
19. Li M, Carpio DF, Zheng Y, Bruzzo P, Singh V, Ouaaz F, Medzhitov RM, and Beg AA. An essential role of the NF-κ B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 166: 7128-7135, 2001.
20. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, and Mak TW. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13: 1015-1024, 1999.
21. Macnicol MF, Goldberg AH, and Clowes GH Jr. Depression of isolated heart muscle by bacterial endotoxin. J Trauma 13: 554-558, 1973.
22. McMurray JJ and Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 83: 596-602, 2000.
23. Medzhitov R, Preston-Hurlburt P, and Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397, 1997.
24. Muzio M, Natoli G, Saccani S, Levrero M, and Mantovani A. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 187: 2097-2101, 1998.
25. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, Nakao K, Nakamura K, Katsuki M, Yamamoto T, and Inoue J. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4: 353-362, 1999.
26. Nemoto S, Vallejo JG, Knuefermann P, Misra A, Defreitas G, Carabello BA, and Mann DL. Escherichia coli LPS-induced LV dysfunction: role of Toll-like receptor-4 in the adult heart. Am J Physiol Heart Circ Physiol 282: H2316-H2323, 2002.
27. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, and Anker SD. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353: 1838-1842, 1999.
28. Ohashi K, Burkart V, Flohe S, and Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 164: 558-561, 2000.
29. Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, and Visner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J Clin Invest 90: 389-398, 1992.
30. Parker JL and Adams HR. Development of myocardial dysfunction in endotoxin shock. Am J Physiol Heart Circ Physiol 248: H818-H826, 1985.
31. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, and Parrillo JE. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100: 483-490, 1984.
32. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, and Schuette W. A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 76: 1539-1553, 1985.
33. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, and Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088, 1998.
34. Schreiber E, Matthias P, Muller MM, and Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17: 6419, 1989.
35. Schulz R, Panas DL, Catena R, Moncada S, Olley PM, and Lopaschuk GD. The role of nitric oxide in cardiac depression induced by interleukin-1β and tumour necrosis factor-α. Br J Pharmacol 114: 27-34, 1995.
36. Shames BD, Meldrum DR, Selzman CH, Pulido EJ, Cain BS, Banerjee A, Harken AH, and Meng X. Increased levels of myocardial IκB-α protein promote tolerance to endotoxin. Am J Physiol Heart Circ Physiol 275: H1084-H1091, 1998.
37. Starr RG, Lader AS, Phillips GC, Stroman CE, and Abel FL. Direct action of endotoxin on cardiac muscle. Shock 3: 380-384, 1995.
38. Stein B, Frank P, Schmitz W, Scholz H, and Thoenes M. Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol 28: 1631-1639, 1996.
39. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, and Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321: 280-287, 1989.
40. Swantek JL, Cobb MH, and Geppert TD. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-α) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol Cell Biol 17: 6274-6282, 1997.
41. Swantek JL, Tsen MF, Cobb MH, and Thomas JA. IL-1 receptor-associated kinase modulates host responsiveness to endotoxin. J Immunol 164: 4301-4306, 2000.
42. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, and Simon JC. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 195: 99-111, 2002.
43. Thomas J, Tsen M, White DJ, and Horton JW. IRAK contributes to burn-triggered myocardial contractile dysfunction. Am J Physiol Heart Circ Physiol 283: H829-H836, 2002.
44. Thomas JA, Allen JL, Tsen M, Dubnicoff T, Danao J, Liao XC, Cao Z, and Wasserman SA. Impaired cytokine signaling in mice lacking the IL-1 receptor-A associated kinase. J Immunol 163: 978-984, 1999.
45. 21 block burn-induced myocardial contractile dysfunction. Am J Physiol Heart Circ Physiol 283: H1645-H1655, 2002.
46. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, and Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27: 1201-1206, 1996.
47. Vig E, Green M, Liu Y, Donner DB, Mukaida N, Goebl MG, and Harrington MA. Modulation of tumor necrosis factor and interleukin-1-dependent NF-kappaB activity by mPLK/IRAK. J Biol Chem 274: 13077-13084, 1999.
48. Wesche H, Henzel WJ, Shillinglaw W, Li S, and Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 7: 837-847, 1997.